New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective-Reference-Cited by-同舟云学术

New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective

Published:2020-06 Issue: Volume:107 Page:154218
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Katsiki Niki,Ferrannini Ele,Mantzoros Christos

Funder

Angelini

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference67 articles.

1. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Buse;Diabetes Care,2020

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

3. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Cosentino;Eur Heart J.,2020

4. Pharmacology of metformin – an update;Glossmann;Eur J Pharmacol,2019

5. Metformin: diamonds are forever;Papanas;Expert Opin Pharmacother,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cardiac-Kidney-Liver (CKL) syndrome: the “real entity” of type 2 diabetes mellitus;Archives of Medical Science;2024-01-31

2. Advancing diabetes treatment: novel formulation of polydatin long-circulating liposomes and their glucose-regulating impact on hyperlipidemia-induced type 2 diabetic mice;Materials Advances;2024

3. Liver fat as risk factor of hepatic and cardiometabolic diseases;Obesity Reviews;2023-08-08

4. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-06-13

5. CARDIOPROTECTIVE AND METABOLIC EFFECTS OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH SUCH COMORBIDITIES AS ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS, AND OBESITY;Bulletin of Problems Biology and Medicine;2023